ArticleFrontiers in oncology2025
Global, regional, and national burden of lung cancer attributable to second-hand smoke from 1990 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Continuous multidimensional physiological monitoring redefines early warning and preemptive treatment for neutropenic sepsis following cisplatin chemotherapy in non-small cell lung cancer.Frontiers in pharmacology · 2026Article
- Editorial: Increasing Awareness of Lung Cancer in Non-Smokers and Never-Smokers Challenges Current Approaches to Prevention and Screening.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Second-hand smoke (SHS) exposure significantly contributes to lung cancer development, yet its global burden remains poorly quantified. Method: Using data from the Global Burden of Disease Study 2021, we analyzed SHS-related lung cancer deaths, disability-adjusted life-years (DALYs), and corresponding age-standardized rates (ASRs) across different regions and countries, stratified by gender, age, and Socio-Demographic Index (SDI). The estimated annual percentage changes (EAPCs) in the ASRs were calculated to determine the temporal trends spanning from 1990 to 2021. We also quantified the relationship between the SDI and the age-standardized rates of lung cancer caused by SHS. Results: In 2021, SHS accounted for approximately 0.10 million lung cancer deaths and 2.37 million DALYs worldwide, with a male-to-female mortality ratio of 1.38. The age-standardized mortality rate (ASMR) and age-standardized DALY rate (ASDR) manifested a trend of decline, with EAPC of -0.88 (95% UI: -0.94 to -0.82) and -1.25 (95% UI: -1.31 to -1. 19), respectively. The ASMR or ASDR peaked in middle and high-middle SDI regions, with a lower burden in other SDI regions. Nevertheless, the ASMR and ASDR in the high SDI region witnessed the most significant decline. Men bore a heavier burden of lung cancer attributable to SHS compared with women. The sexual disparity was more conspicuous among the elderly. Conclusion: During the past 32 years, the global burden of lung cancer attributable to SHS has revealed a downward tendency, concomitant with a decline in SHS exposure. The rise in absolute deaths and DALYs is driven by population growth and aging despite falling ASRs. Persistent epidemiological disparities across genders, age groups, and regions underscore the need for targeted interventions, particularly in middle and high-middle SDI settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.